Revolution Medicines, Inc. (RVMD)

NASDAQ: RVMD · IEX Real-Time Price · USD
30.38
+0.64 (2.15%)
At close: Feb 26, 2024, 4:00 PM
30.40
+0.02 (0.07%)
After-hours: Feb 26, 2024, 5:34 PM EST
2.15%
Market Cap 4.91B
Revenue (ttm) 11.58M
Net Income (ttm) -436.37M
Shares Out 163.80M
EPS (ttm) -3.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 851,449
Open 29.86
Previous Close 29.74
Day's Range 29.62 - 30.68
52-Week Range 15.44 - 35.60
Beta 1.54
Analysts Strong Buy
Price Target 35.82 (+17.91%)
Earnings Date Feb 26, 2024

About RVMD

Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H),... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2020
Employees 246
Stock Exchange NASDAQ
Ticker Symbol RVMD
Full Company Profile

Financial Performance

In 2023, RVMD's revenue was $11.58 million, a decrease of -67.27% compared to the previous year's $35.38 million. Losses were -$436.37 million, 75.5% more than in 2022.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price forecast is $35.82, which is an increase of 17.91% from the latest price.

Price Target
$35.82
(17.91% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

10 hours ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today...

6 days ago - GlobeNewsWire

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...

25 days ago - GlobeNewsWire

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...

7 weeks ago - GlobeNewsWire

Revolution Medicines Completes Acquisition of EQRx

Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines' Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs

3 months ago - GlobeNewsWire

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

REDWOOD CITY, Calif. and CAMBRIDGE, Mass.

3 months ago - GlobeNewsWire

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

Promising clinical data for RMC-6236, a RAS MULTI (ON) Inhibitor, and RMC-6291, a RAS G12C (ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings

4 months ago - GlobeNewsWire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112 Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112

4 months ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today...

4 months ago - GlobeNewsWire

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time

4 months ago - GlobeNewsWire

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

Clinical dose escalation data for RMC-6236, a RAS MULTI (ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mut...

4 months ago - GlobeNewsWire

EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of EQRx, Inc. (Nasd...

5 months ago - Business Wire

Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CUTROMGAVNRX
5 months ago - Benzinga

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

Interim Data to be Presented for RMC-6236 (RAS MULTI (ON) Inhibitor) and RMC-6291 (RAS G12C (ON) Inhibitor)

5 months ago - GlobeNewsWire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers

5 months ago - GlobeNewsWire

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

Science Report on KRAS G12C (ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline

6 months ago - GlobeNewsWire

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and initial clinical findings for RMC-6291 at Triple ...

7 months ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today...

7 months ago - GlobeNewsWire

RVMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Revolution Medicines, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Revolution Medicines, Inc. (NASDAQ: RVMD) and EQRx, Inc. is fair to Revolution Medicine...

7 months ago - Business Wire

Revolutin Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D

Revolution Medicines Inc. RVMD, +2.10% said Tuesday it has reached a definitive agreement to acquire EQRx Inc. EQRX, in an all-cash deal that's expected to add more than $1 billion in net cash to its ...

7 months ago - Market Watch

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

R evolution Medicines Expect s to Conduct Late-Stage Development of RAS(ON) I nhibitor Drug C andidate Pipeline Supported by Fortified Balance Sheet

7 months ago - GlobeNewsWire

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RAS MULTI), RMC-6291 (KRAS G12C) and RMC-9805 (KRAS G12D) – progressing on plan

10 months ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today ...

10 months ago - GlobeNewsWire

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

Where is the current bull market? All indications would be that it's in biotech!

11 months ago - Benzinga

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today anno...

11 months ago - GlobeNewsWire